Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.14-0.31 (-4.81%)
At close: 04:00PM EST
6.33 +0.19 (+3.09%)
After hours: 07:46PM EST
Advertisement
Sign in to post a message.
  • G
    Gabriele
    The NCT02297698 https://clinicaltrials.gov/ct2/show/NCT02297698 ‘Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+)’ says ‘Estimation primary completion date is December 2021’.

    The recruitment status changed from ‘active, recruiting’ to ‘active, not recruiting’ on the 6th of Dec 2018 (info from the same website).

    Sellas reports https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update/default.aspx : ‘In January 2021, the data safety monitoring board recommended, with respect to the ongoing investigator sponsored study of NPS plus trastuzumab in high risk HER2 3+ breast cancer patients that, given the small size of the study and in order to preserve the statistical power of the study, the primary analysis of the study be completed upon the completion of three years of follow-up on every patient or until more events are collected’.

    Time has matured.

    Of note: The events they mention relate to the primary end-point ‘invasive disease’.
    We can deduct -to stay conservative - that in the last 12 months not enough ‘events’ occurred in the NPS arm, which seems to be a good sign.
    Let's wait and see.
    Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients - Full Text View.
    Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients - Full Text View.
    clinicaltrials.gov
  • g
    ggrail
    If and until SLS actually provides timelines that are concrete and not "imminent" or deals that are actually announced and not "hinted at" or completes phase 3 studies with positive published results, or does a deal with a larger pharma, it will remain a sheer speculative play and be at the mercy of those that wish to make money manipulating others opinions one way or another. The small float is both friend and foe in all of this and the number of shares insti's hold is still relatively small. Waiting for published positive results and announcements that actually add value to the stock are all that matters and those have been managed less than professionally by current management who may be great at one aspect but do not meet the mark as having what it takes to actually realize the potential of the company should all the studies pan out in their favor.
  • j
    james
    When all the scammers are posting about SLS being a scam keep in mind, the Chairman of MD Anderson’s Leukemia Dept, a guy with 20 FDA approvals, said this:- “Given these results, (21 months of Survival vs 5 with Best available treatment) it is particularly exciting to be involved in the ongoing pivotal Phase 3 REGAL study of GPS in AML patients in CR2 said Hagop M. Kan.tarjian, MD, REGALs principal investigator. We are working to rapidly enroll patients who meet entry criteria for this study and believe these compelling results will enhance the visibility of this novel therapy and encourage broader participation in the pivotal Phase 3 trial."
    Bullish
  • j
    james
    “Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company’s lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein”
    Dr. Jeffrey Weber, a specialist in cancer immunotherapy, is currently director of the Perlmutter Cancer Center and the co-director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is principal investigator on several ongoing studies funded by the National Cancer Institute (NCI) as well as industry, including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He earned his PhD in molecular biology from Rockefeller University (NY) in 1979 and his MD from New York University in 1980. Dr. Weber sat on the NCI’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He has published more than 150 articles in the top peer-reviewed journals in his field.
    Bullish
  • j
    jim
    THE GLSI DOCS SAY NPs IS MORE EFFECTIVE - Nps Results imminent Be Holding $29 $49 Possible Instantly
    GLSI Stock: Why Greenwich LifeSciences Is Up 2,000% Today 12/9/2020 2:33pm EST By Sarah Smith
    You may not have heard of Greenwich LifeSciences (NASDAQ:GLSI) before today, but that is not stopping GLSI stock from soaring more than 2,000% on Wednesday. This comes as the biopharmaceutical company shared promising results on its breast cancer treatment.
    --> Dr Mittendorf/ Peoples “Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’

    The website https://clinicaltrials.gov/ct2/show/NCT02297698 says ‘Estimation primary completion date is December 2021
    Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients - Full Text View.
    Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients - Full Text View.
    clinicaltrials.gov
    Bullish
  • j
    james
    Chairman of the Leukemia Dept at the University of Texas MD Anderson Cancer Center - “Given these results, (21 months of Survival vs 5 with Best available treatment) it is particularly exciting to be involved in the ongoing pivotal Phase 3 REGAL study of GPS in AML patients in CR2 said Hagop M. Kan.tarjian, MD, REGALs principal investigator. We are working to rapidly enroll patients who meet entry criteria for this study and believe these compelling results will enhance the visibility of this novel therapy and encourage broader participation in the pivotal Phase 3 trial."

    Hard to know the truth seeing as how dman keeps saying this is a scam
    Bullish
  • R
    Real Immuno Investor 10
    Her 2 Phase 2B Trial results Imminent - virtually identical to Data that Launched glsi 2,000%. Co Twitter and Linkdin accounts activated - “stay tuned”. Best Investment opportunity in the whole market right here right now.
    Bullish
  • R
    Real Immuno Investor 10
    Her 2 Phase 2B Trial results Imminent - virtually identical to Data that Launched glsi 2,000%. Co Twitter and Linkdin accounts activated - “stay tuned”. Best Investment opportunity in the whole market right here right now. Buy More.
    Bullish
  • y
    y
    Message to this board: In my years, I have seen many stocks sell for what appeared to be VERY low prices. SLS is one of them. One day I expect hope to explode here. In the meantime, just have to wait. Patience is NOT GUARANTEED to be rewarded, but it seems likely. And IF this works, and it works on the other 20 indications that seem possible, this is going to be a HUGE winner.

    I remember when Cramer use to dis ELN (Elan) before Tysabri became a huge drug for the MS community. And how stories would be repeated in the AP (press) that just weren't true. It was if someone told one story and everyone else didn't do their homework and just repeated the mistakes (lies?).

    There is RISK here, but the story is strong and the risk/reward ratio is really strong. I am excited about buying at these prices. Sometimes the market just gives great deals. SLS appears to be one of them. I look forward to the future . . .

    SLS: $6.14 close (hit a low of $6.00 b today)
  • P
    P509$
    Interesting Bolt from the Blue potential Phase 3 REGAL Study:
    Additional sites in the United States and European Union were activated during the third quarter with enrollment continuing. In addition, regulatory approval to commence the REGAL study was received in both Hungary and Taiwan during the quarter.
    The final statistical analysis plan (SAP) for the REGAL study provides for a planned interim safety and futility analysis after 80 events (deaths) which the Company had anticipated would take place in the first half of 2022, provided that the ongoing COVID-19 pandemic did not significantly adversely impact our projected timeline for enrollment. Over the last 12 to 18 months, the Company has monitored the impact of the COVID-19 pandemic on the projected timeline for the REGAL study. During this period, the Company took several steps to mitigate possible and actual delays due to the COVID-19 pandemic, including increasing the number of clinical sites and the number of countries in which sites are located in order to maintain the original timeline. Despite these mitigation steps, the Company now anticipates that the interim analysis will take place in the second half of 2022, provided that the ongoing COVID-19 pandemic does not continue to adversely impact the projected timeline for enrollment. In addition to the planned interim analysis under the SAP, the final charter for the Independent Data Monitoring Committee for the REGAL study provides for enrollment-based safety, futility, and efficacy analyses prior to the planned interim analysis.
    Bullish
  • D
    Dangremaus
    Which would you rather invest in? A company with excellent news pending in the next 6 months or an overpriced security with average news? I choose the former. That’s value investing. The current stock price decline of $4-5 won’t matter compared to a gain of $100’s of dollars in the near future.
  • R
    Real Immuno Investor 10
    In January 2021, the data safety monitoring board recommended, with respect to the ongoing investigator sponsored study of NPS plus trastuzumab in high risk HER2 3+ breast cancer patients that, given the small size of the study and in order to preserve the statistical power of the study, the primary analysis of the study be completed upon the completion of three years of follow-up on every patient or until more events are collected. The Company expects the primary analysis in this study to be completed by the end of 2021.
    Bullish
  • E
    ExPharmaGuy
    I increased my position today. I am very impressed that someone as renowned as Hagop #$%$arjian is intimately associated with this drug. If you know Hematologists, typically they do not get excited about drugs. His remarks about seeing increasing OS are not made lightly. Moreover, now that he heads the dept at the largest cancer center in the world, he can encourage recruitment to whatever IRB approved protocols testing Galinpepimut-S are open. Finally, past legal problems appear to have been settled.
  • j
    james
    When all the scammers posting about SLS being a scam keep in mind, the Chairman of MD Anderson’s Leukemia Dept, a guy with 20 FDA approvals, said this:- “Given these results, (21 months of Survival vs 5 with Best available treatment) it is particularly exciting to be involved in the ongoing pivotal Phase 3 REGAL study of GPS in AML patients in CR2 said Hagop M. Kan.tarjian, MD, REGALs principal investigator. We are working to rapidly enroll patients who meet entry criteria for this study and believe these compelling results will enhance the visibility of this novel therapy and encourage broader participation in the pivotal Phase 3 trial."
    Bullish
  • S
    Stephens
    What will the share price be when Nelipepimut results come out? What will the price be when the License deal is announced? What about when the Memorial Sloan Kettering Gps + Opdivo Mesothelioma results are out in Jan? How about the Gps + Keytruda Advanced Ovarian Cancer results, also in Jan? My Guess is somewhere north of $20. What will the share price be when the AML Phase 3 results hit ? My guess is somewhere north of 100 per share. SLS Has a tiny little number of shares floating and as you can see many short interests are manipulating the price, for the time being.
    Bullish
  • J
    Joe
    I’ll give them until Xmas to do their job and keep us informed otherwise I’m out. Thank believe I own more shares than most here. It’s been a year of empty promises so far
  • R
    Real Immuno Investor 10
    Results Imminent Nps better than Glsi drug $29 49 possible from Dr Mittendorf/ Peoples Glsi Trial Docs “Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’
    The website https://clinicaltrials.gov/ct2/show/NCT02297698 says ‘Estimation primary completion date is December 2021’
    I see now that during the SABC Symposium 2021 (7-10 Dec 2021), there is a Spotlight Session https://www.sabcs.org/Program/Daily-Schedule/Day-3
    Poster Session 4 Hall 1 (from 5.00 to 6.30 PM)
    Where Mittendorf will attend to discuss ‘Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches’
    Bullish
  • R
    Real Immuno Investor 10
    https://clinicaltrials.gov/ct2/show/NCT02297698 ‘Estimation primary completion date is December 2021’
    Results Imminent -- Nps better than Glsi drug $29 $49 possible from Dr Mittendorf/ Peoples Glsi Trial Docs “Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’
    The website https://clinicaltrials.gov/ct2/show/NCT02297698 says ‘Estimation primary completion date is December 2021’
    I see now that during the SABC Symposium 2021 (7-10 Dec 2021), there is a Spotlight Session https://www.sabcs.org/Program/Daily-Schedule/Day-3
    Poster Session 4 Hall 1 (from 5.00 to 6.30 PM)
    Where Mittendorf will attend to discuss ‘Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches’
    Bullish
  • R
    Real Immuno Investor 10
    Nps ~ Phase 2B Herceptin results for HER2 BC any day -Another success like Nps + Herceptin for TNBC or a result like $Glsi could more than double or triple the share price instantly
    - when it hits. Nct site updated Nov 16 - something is about to happen. Ceo in Aug, “Stay tuned for a Nps Announcement “ and “its $roche” in June
    Herceptin is ineffective In TNBc sans Nps - it only works with NPS https://ascopubs.org/doi/10.1200/JCO.2019.37.8_suppl.1
    Final analysis of nelipepimut-S plus GM-CSF with trastuzumab

    * Also, Two Binary readouts in January. Gps+Keytruda Ovarian results , the additional 6 months time will confirm OS better than soc of 9-12months, remeber ALL GPS/key patients were alive at the 9 months mark.
    1 Background: Preclinical data shows synergism between trastuzumab (Tz) and HER2-targeted vaccines. We evaluated adjvuant nelipepimut-S (NPS) + GM-CSF with Tz compared to Tz with GM-CSF alone in HER2 low-expressing (LE) breast cancer (BC) patients (p
    1 Background: Preclinical data shows synergism between trastuzumab (Tz) and HER2-targeted vaccines. We evaluated adjvuant nelipepimut-S (NPS) + GM-CSF with Tz compared to Tz with GM-CSF alone in HER2 low-expressing (LE) breast cancer (BC) patients (p
    ascopubs.org
  • c
    citadel_short
    Despite the loss of credibility for this ceo, there may be value in nps, gps from the prior trials. I am disappointed the ceo is slow and doesn’t execute strategically, best outcome is to put part or whole of company for sale… Angelos may be good at working the process, let him get absorbed in doing the work and research with others but planning, strategizing and managing better done at a bigger company.

    My 2c on how the co managed itself do far and set itself on a negative perception trend (bringing in hawks to market on message board, continuous pumping, no proper carrots for investors etc)
Advertisement
Advertisement